Figure 6
From: CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis
CD14+cells from HC and PsA respond differently to TNFα in regards to CD16 cell surface expression. The expression of CD16 on freshly isolated peripheral blood mononuclear cells (PBMC) from healthy control (HC) and psoriatic arthritis (PsA) was shown in (a) and (b), respectively. After PBMC were cultured in the (c and e) absence or (d and f) presence of TNFα for three days, cell surface expression of CD16 was examined again using the same antibody cocktail composed of anti-CD16 (PE), anti-CD14 (APC), anti-CD3 (Pacific Blue), and anti-CD19 (APC-Cy7) antibodies with 7AAD. The anti-CD3, anti-CD19 antibodies and 7AAD were included to exclude T cells, B cells, and dead cells, respectively. Numbers shown in each quadrant (c to f) represent the percentage of cells per total gated live cells. Data shown here are the representative of two HC and three PsA samples.